FTC Eyes Evolving Pay-For-Delay Drug Deals
The Federal Trade Commission indicated Wednesday that it would take a hard-line approach to pay-for-delay deals in which brand-name drugmakers promise not to introduce their own generic treatments in exchange for...To view the full article, register now.
Already a subscriber? Click here to view full article